MassDevice.com +5 | The top 5 medtech stories for March 29, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. The exodus of key personnel at Google’s Verily There’s reportedly a rare exodus under way of key personnel from a Google operation, its Verily healthcare “moonshot,” with former employees blaming the mercurial leadership of CEO Andrew Conrad. A dozen top engineers, scientists and managers have departed since Verily, formerly Google Life Sciences, was launched 3 years ago, according to the Stat website. Read more 4. Report: U.S. IPOs hit 7-year low during 2016 1st quarter The U.S. market for initial public offerings hit its lowest mark during the 1st quarter since the financial crisis hit in 2008 and 2009 and every flotation was for a healthcare company, according to a report from Renaissance Capital. Eight IPOs raised a collective $700 million during the quarter, but were only viable due to substantial buys from existing shareholders, according to the report. Read more 3. St. Jude wins CE Mark for expanded suite of cardiac leads St. Jude Medical said today it won CE Mark approval in the European Union and launched 3 new Quartet left ventricular...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news

Related Links:

RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Conclusion Coagsense correlated better than Coagucheck XS and did not show increasing bias as INR increased. Both POC instruments had higher INR variability in 4 disease states (antiphospholipid syndrome, autoimmune, peripheral vascular disease, and hypercoagulable). Patient-specific laboratory correlations may be needed on each POC device.
Source: Point of Care: The Journal of Near-Patient Testing and Technology - Category: Pathology Tags: Original Articles Source Type: research
Conclusions: Embolism associated with asymptomatic carotid stenosis shows circadian variation with highest rates 4–6 h before midday. This corresponds with peak circadian incidence of stroke and other vascular complications. These and ASED Study results show that monitoring frequency, duration, and time of day are important in ES detection. Introduction Transcranial Doppler (TCD) detected microembolism in the ipsilateral middle cerebral artery (MCA) may help stratify the risk of stroke and other arterial disease complications in persons with advanced (≥60%) asymptomatic carotid stenosis. If so, this techniqu...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Abstract Oral anticoagulants (OAC) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome (ACS), treated by percutaneous coronary intervention (PCI). In recent years, with the introduction of NOACs, triple or dual therapy has become safer. Regardless of these indications for...
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research
AbstractWith the advent of transcatheter aortic valve replacement (TAVR), appropriately selected intermediate-, high-, and extreme-risk patients with severe aortic stenosis (AS) are now offered a less invasive option compared to conventional surgery. In contemporary practice, TAVR is performed predominantly via a transfemoral arterial approach, whereby a transcatheter heart valve (THV) is delivered in a retrograde fashion through the iliofemoral arterial system and thoraco-abdominal aorta, into the native aortic valve annulus. While the majority of patients possess suitable anatomy for transfemoral arterial access, there i...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Siemens (NYSE:SI) Healthineers said today it tapped former Abbott (NYSE:ABT) Vascular president Dr. Deepak Nath as its new laboratory diagnostics business president, taking over for Franz Walt who operated as president from 2014 to 2017. Nath spent 10 years with Abbott, serving most recently as its vascular division president and as an executive officer of the company, and as president of the molecular diagnostics division prior to that. He also operated as GM of Ibis Biosciences, and has held positions at Amgen (NSDQ:AMGN) and McKinsey. “Siemens Healthineers seeks to benefit from market oppo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Abbott aligntechnology Amgen Cardiovascular Systems Inc. CHF Solutions Inc. Cook Group Inc. Endologix Hill-Rom Holdings Inc. Invetech johnsonandjohnson lohmannandrauscher Medtronic Neuromod Devices Novar Source Type: news
In this study, 63% of patients in the CVS group and 82% in the ERS group were defined as HRI. One in-hospital death was documented after 30 days. With regards to the HRI cohort, no difference in rates of PM use were noted (ERS 20% versus CVS 20%; p>0.9999). ERS patients were characterized by a higher prevalence of peripheral vascular disease (PVD) (46% versus 21%; p
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Conclusions:The incidence of ischemic optic neuropathy in cardiac surgery did not change over the study period. Development of ischemic optic neuropathy after cardiac surgery is associated with male gender, carotid artery stenosis, peripheral vascular disease and degenerative eye conditions.Study Supported by:Funding was provided by National Institutes of Health (Bethesda, Maryland) grants RO1 EY10343 to Dr. Roth, UL1 RR024999 to the University of Chicago Institute for Translational Medicine, UL1TR002003 to the University of Illinois at Chicago Center for Clinical and Translational Science, K23 EY024345 to Dr. Moss, Core G...
Source: Neurology - Category: Neurology Authors: Tags: Neuro-ophthalmology/Neuro-Otology Source Type: research
Authors: Panoulas VF, Ruparelia N, Franks R, Sen S, Ariff B, Sutaria N, Frame A, Nihoyannopoulos P, Malik IS, Mikhail GW Abstract Transcatheter aortic valve implantation (TAVI) is currently the treatment of choice for patients with severe aortic stenosis (AS) who are unsuitable for surgical aortic valve replacement (SAVR), and is an acceptable alternative for those at high and intermediate surgical risk. In published TAVI registries and meta-analyses, whilst women are significantly older they present with fewer comorbidities compared to men (including coronary artery disease, peripheral vascular disease, diabetes a...
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
More News: Cardiac Resynchronization Therapy | Cardiology | Clinical Trials | Health | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Medical Devices | Peripheral Vascular Disease (PVD) | Study | Websites